Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE
Emma M. Kileel(Boston University), Heather J Ribaudo(Cancer Research And Biostatistics), Nwora Lance Okeke(Duke University), Janet Lo(Harvard University), Alana T. Brennan(Boston University), Jordan E. Lake(The University of Texas Health Science Center at Houston), Steven Grinspoon(Massachusetts General Hospital), Carlos Malvestutto(The Ohio State University Wexner Medical Center), Gerald S. Bloomfield, Princy Kumar(Georgetown University), Judith A. Aberg(Icahn School of Medicine at Mount Sinai), Daniel Berrner(San Francisco General Hospital), Esteban Martinez(Instituto de Salud Carlos III), Carl J Fichtenbaum(University of Cincinnati), Alex B Lu(Harvard University), Michael T. Lu(Harvard University), Emma Davies-Smith(Cancer Research And Biostatistics), Marissa R Diggs(Harvard University), Sara H Bares(University of Nebraska Medical Center), Aya Awwad(Harvard University), Matthew P Fox(Boston University), Judith S Currier(University of California, Los Angeles), Pamela S Douglas(Duke University), Kunjal Patel(Cancer Research And Biostatistics), Marek Smieja(McMaster University), Markella V. Zanni(Harvard University), Esau João(Hospital Federal dos Servidores do Estado), Sarah M Chu(Harvard University)
Cited by 2
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease
|The Journal of Clinical Endocrinology & Metabolism|2007|1.6k
Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults
|New England Journal of Medicine|2005|1.1k